Cytokinetics, Inc.
(NASDAQ : CYTK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.24%63.151.0%$510.50m
AMGNAmgen, Inc. -4.02%225.591.3%$451.51m
BIIBBiogen, Inc. -2.14%278.141.4%$375.15m
ILMNIllumina, Inc. -2.27%319.583.5%$322.74m
VRTXVertex Pharmaceuticals, Inc. -2.07%229.061.9%$273.01m
REGNRegeneron Pharmaceuticals, Inc. -3.17%345.282.6%$238.76m
EXASEXACT Sciences Corp. -2.83%89.5724.0%$223.37m
ALXNAlexion Pharmaceuticals, Inc. -3.02%105.272.0%$170.84m
AAgilent Technologies, Inc. -0.92%88.251.6%$130.79m
INCYIncyte Corp. -1.92%76.742.5%$127.16m
BMRNBioMarin Pharmaceutical, Inc. 0.61%86.154.3%$108.27m
SRPTSarepta Therapeutics, Inc. -1.14%112.3914.6%$108.00m
SGENSeattle Genetics, Inc. -1.54%113.576.1%$103.89m
BLUEbluebird bio, Inc. -2.74%87.2614.2%$86.40m
DERMDermira, Inc. -0.27%18.713.8%$83.32m

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.